Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New app aims to help black adults with HIV kick the habit and ease anxiety

NCT ID NCT07024992

Disease control Sponsor: University of Houston Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This study tests a smartphone app called ESCAPE, designed specifically for Black adults with HIV who smoke. The app teaches ways to handle stress, anxiety, and nicotine cravings, and is paired with nicotine patches or gum. 300 participants across the US will be randomly assigned to the ESCAPE app, a standard quit-smoking app, or just nicotine replacement. The goal is to see if the tailored app helps more people quit smoking and improves mental health and HIV care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ESCAPE app (behavioral intervention) plus nicotine replacement therapy (NRT)
What this could lead to
If successful, this could provide an effective, culturally tailored tool to help Black adults with HIV quit smoking and improve mental health and HIV management.
What could go wrong
This is a Phase 2 trial with 300 participants, so results are preliminary. The app may not work better than standard treatments, and adherence to the app or NRT could be low.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * At least 18 years of age * Identify as Black/African American * Living with HIV * Biochemical verification of self-reported smoking status following minimum study specified smoking rate endorsement * Motivated to quit smoking * Must be ready to quit cigarettes within 14 days of full enrollment * Moderate or higher anxiety sensitivity OR elevated anxiety OR depression * Must be willing to download a mobile app onto their personal phone * Must be willing to use NRT * Possess an Android/Apple smartphone that is compatible with the mobile app * Demonstrate 7th grade level proficiency in English (≥4 on the Rapid Estimate of Adult Literacy in Medicine-Short Form \[REALM-SF\]) * Valid proof of identification (photo of valid US ID) Exclusion Criteria: * Legal situations which may interfere with study participation * Not being fluent in English * High blood pressure that is not under control * Having experienced a heart attack within the past 2 weeks * Pregnant of planning to become pregnant within the next six months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CTRL+NRT are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease nicotine dependence Smoking Smoking Cessation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CTRL+NRT Escape intervention+NRT Quitstart intervention+NRT

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Oklahoma Health Sciences Center

    RECRUITING

    Oklahoma City, Oklahoma, 73104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.